One year after TGA approval, Yorvipath remains inaccessible in Australia. PBS listing is currently dependent on price negotiations.

Yorvipath is already available in many other countries, where patients report improved calcium stability, fewer hospital visits, and meaningful improvements in daily functioning. Australia risks falling behind in providing standard-of-care hormone replacement for a permanent endocrine deficiency. Funding priorities should align with clinical evidence and long-term system sustainability.